HTG Molecular Diagnostics and Sanofi US Collaborate to Identify B-cell Malignancy Biomarkers Development of tests that help identify patients most likely to respond to targeted therapy is a key step toward the personalization of medicine TUCSON, Ariz.
February 13, 2012 TUCSON, Ariz. — HTG Molecular , a privately-held, Tucson-based provider of molecular-technology solutions, added three industry-renown professionals to its executive team: Shaun McMeans , Vice President of Finance, Administration and Chief Financial Officer; Timothy J Holzer,
